PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Bioactive Materials0 citationsOpen Access

Integrated cryopreservation-thawing-transplantation platform for neural stem cell-based spinal cord injury repair

View Full Paper
JRJie RenJLJunjin LiHWHongda Wang

Key Points

  • High cell viability retention is achieved using the integrated platform during cryopreservation and thawing, significantly improving outcomes.
  • The bioactive material PM-BMH@Exo ensures directed differentiation while maintaining stemness in neural stem cells after thawing.
  • Integration of cryopreservation, thawing, and transplantation within a closed system enhances operational standardization and reduces contamination risks.
  • Systematic in vitro and in vivo evaluations confirm the platform's effectiveness, highlighting its potential for clinical translation in spinal cord injury repair.

Abstract

Spinal cord injury (SCI) repair lacks clinically validated restorative therapies. Transplantation of exogenous neural stem cells (NSCs) offers significant potential for therapeutic applications; however, challenges remain, including substantial cell loss, uncontrolled differentiation, and limited tissue integration within inflammatory microenvironments. Furthermore, the workflow associated with traditional NSC transplantation-including cryopreservation, thawing, transportation, and injection-remains fragmented, resulting in systemic limitations. These issues manifest as reduced cell viability and stemness, an elevated risk of contamination, and dosing inaccuracies. All these significantly impede clinical translation. An integrated system for NSC preservation, transport, and transplantation is required to meet the following criteria: (i) maintenance of high cell viability and stemness post-cryopreservation and thawing; (ii) modulation of the acute-phase immune microenvironment; (iii) regulation of the differentiation fate of transplanted NSCs; (iv) injectable, standardized, and closed-system operation. To meet these requirements, we established a comprehensive cryopreservation, thawing, and transplant (CTT) integrated platform. Utilizing the bioactive material PM-BMH@Exo, this platform enables seamless end-to-end workflow integration through a mechanism that preserves bioactivity. It not only ensures high viability retention and directed differentiation of NSCs but also effectively mitigates the rapid viability decline of cells observed after traditional cryopreservation. Furthermore, the system enables closed-loop operations spanning cryopreservation, thawing, and minimally invasive injection. It breaks through systemic bottlenecks from multi-step procedures, comprehensively enhancing the timeliness and standardization of therapeutic interventions. We systematically evaluated the system's feasibility and efficacy via in vitro and in vivo experiments. This study presents a technologically viable and clinically compatible pathway with potential applications for SCI repair.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ren et al. (2026) studied this question.

synapsesocial.com/papers/69a75f86c6e9836116a2af49https://doi.org/10.1016/j.bioactmat.2026.01.024
Ask AI
Helpful
Bookmark
Share
View Full Paper